An important milestone for innovation in urology: the latest guidelines from the European Association of Urology on the management of male lower urinary tract symptoms (LUTS) now recognize transperineal laser ablation (TPLA) among emerging ablative techniques.
This update sends a clear message: the demand for increasingly minimally invasive and targeted therapeutic solutions continues to grow, with the goal of improving patient quality of life while reducing procedural impact.
In this evolving landscape, EchoLaser stands out as an advanced technology, offering a precise, customizable, and image-guided approach for the treatment of conditions such as benign prostatic hyperplasia (BPH).
Inclusion in the EAU guidelines is not only a scientific recognition, but also a confirmation of the clinical value and future potential of laser ablation in the global urology field.
We will continue to support the medical community in developing effective, safe, and patient-centered solutions.
👉 Discover more in the official EAU guidelines:
https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts/chapter/disease-management